Key Points
HLA I signaling induces robust activation of YAP in human ECs.
Src kinases mediate YAP activation in response to HLA I signaling in ECs.
Src/YAP plays a critical role in HLA I–induced proliferation and migration of ECs.
Abstract
Ab cross-linking of HLA class I (HLA I) molecules on the surface of endothelial cells (EC) triggers proliferative and prosurvival intracellular signaling, which is implicated in the process of chronic allograft rejection, also known as transplant vasculopathy. Despite the importance of Ab-mediated rejection in transplantation, the mechanisms involved remain incompletely understood. In this study, we examined the regulation of yes-associated protein (YAP) localization, phosphorylation, and transcriptional activity in human ECs challenged with Abs that bind HLA I. In unstimulated ECs, YAP localized mainly in the cytoplasm. Stimulation of these cells with Ab W6/32 induced marked translocation of YAP to the nucleus. The nuclear import of YAP was associated with a rapid decrease in YAP phosphorylation at Ser127 and Ser397, sites targeted by LATS1/2 and with the expression of YAP-regulated genes, including connective tissue growth factor (CTGF), and cysteine-rich angiogenic inducer 61 (CYR61). Transfection of small interfering RNAs targeting YAP/TAZ blocked the migration of ECs stimulated by ligation of HLA I, indicating that YAP mediates the increase in EC migration induced by HLA I ligation. Treatment of intact ECs with Src family inhibitors induced cytoplasmic localization of YAP in unstimulated ECs and, strikingly, blocked the nuclear import of YAP induced by Ab-induced HLA I activation in these cells and the increase in the expression of the YAP-regulated genes CTGF and CYR61 induced by HLA I stimulation. Our results identify the Src/YAP axis as a key player in promoting the proliferation and migration of ECs that are critical in the pathogenesis of transplant vasculopathy.
Footnotes
↵1 E.F.R. and E.R. should be considered joint senior authors.
This work was supported by a grant (to E.F.R. and E.R.) of the Connie Frank and Evan Thompson Program for Collaborative Restorative Transplantation Research. E.F.R. is also supported by National Institute of Allergy and Infectious Diseases Grants RO1 AI135201, U19 AI128913, P01AI120944 and U01 AI-124319. E.R. is also supported by National Institute of Diabetes and Digestive and Kidney Diseases Grants R01 DK100405, P30 DK041301, P01CA236585, and Department of Veterans Affairs Merit Award 1I01BX003801.
Abbreviations used in this article:
- AMR
- Ab-mediated rejection
- cAMR
- chronic AMR
- CTGF
- connective tissue growth factor
- EC
- endothelial cell
- FAK
- focal adhesion kinase
- GPCR
- G protein–coupled receptor
- HLA I
- HLA class I
- ID
- identification
- mTOR
- mechanistic target of rapamycin
- mTORC
- mTOR complex
- Non-Targ
- nontargeted negative control
- SFK
- Src family kinase
- siRNA
- small interfering RNA
- TAV
- transplant allograft vasculopathy
- TAZ
- WW-domain–containing transcriptional coactivator with PDZ-binding motif
- TEAD
- TEA domain DNA-binding transcription factor
- YAP
- yes-associated protein.
- Received May 12, 2020.
- Accepted July 27, 2020.
- Copyright © 2020 by The American Association of Immunologists, Inc.
Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$37.50
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.